LRFN5 and major depressive disorder: The significantly higher levels of both molecules in MDD patients compared to HCs and in DN-MDD patients compared to DT-MDD patients suggested that LRFN5 and OLFM4 might be implicated in the pathophysiology of MDD and the mechanisms underlying the therapeutic effects of antidepressants.